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Oligosaccharides present on the surface of pathogenic
bacteria play an important role in their interaction with
their host. Bacteria with altered cell surface structures
can be used to study these interactions, and glycoengi-
neering represents a tool to display a glycoepitope on a
different bacterium. Here, we present non-pathogenic
Escherichia coli and Salmonella enterica serovar Typhi-
murium expressing the sialyllactose oligosaccharide
epitope of the ganglioside GM3. By expression of the ga-
lactosyltransferase LgtE and the sialic acid transferase
Lst as well as the CMP-sialic acid synthetase SiaB from
Neisseria gonorrhoeae and Neisseria meningitidis in engi-
neered strains devoid of the sialic acid catabolism, the
GM3 sugar epitope was displayed on these bacteria as
demonstrated by live cell immunostaining and a detailed
analysis of their lipooligosaccharides. These strains offer
the possibility to investigate the role of sialic acid in the
recognition of bacteria by the immune system in a non-
pathogenic background.
Keywords: bacterial glycosylation/chimeric LPS/
gangliosides/glycoengineering
Introduction
Bacteria produce many oligo- and polysaccharide structures. A
high percentage of these is found in structures of the cell wall,
e.g., in peptidoglycan, lipopolysaccharides (LPS) and lipooli-
gosaccharides (LOS). Some human enteropathogens, like
Campylobacter jejuni and Neisseria meningitidis, produce sac-
charide structures on their surface that resemble human
carbohydrate structures (Tsai 2001; Yuki et al. 2004). This
mechanism is termed molecular mimicry and might help the
bacteria to avoid recognition by the human immune system.
C. jejuni is one of the few bacteria able to synthesize sialic acid
(N-acetyl neuraminic acid; NeuNAc), and many strains include
this sugar in their LOS, resulting in human ganglioside sugar
mimicry (Aspinall, Fujimoto et al. 1994; Aspinall, McDonald
et al. 1994; Ang et al. 2004). Gangliosides are glycosphingoli-
pids containing at least one sialic acid residue. They are present
in all mammalian cells but enriched in nerve cells and in brain
tissue. The molecular mimicry of ganglioside sugar epitopes
can lead to the autoimmune paralysis Guillain–Barré Syn-
drome (GBS) in approximately 1 in 1000 humans infected
with C. jejuni (Ang et al. 2004; Yuki et al. 2004). Patients pro-
duce anti-ganglioside antibodies that do not only bind the
ganglioside sugar epitopes on the surface of the pathogen
but also the host's own gangliosides, mostly in the nodes
of Ranvier and the motor nerve termini (Yuki et al. 1990;
Hafer-Macko et al. 1996).
Recent studies used genetically engineered Escherichia coli
to produce pure oligosaccharides in large quantities. These E.
coli strains heterologously express glycosyltransferases from
other bacteria, e.g., N. meningitidis, Neisseria gonorrhoeae
or C. jejuni or even eukaryotes. The oligosaccharides produced
include the carbohydrate moiety of nonsulfated HNK-1, Lewis
X tetrasaccharides, globotriose and globotetraose, human milk
oligosaccharides and the carbohydrate moieties of the gang-
liosides GM1 and GM2 (Priem et al. 2002; Antoine et al.
2003, 2005; Dumon et al. 2006; Yavuz et al. 2008). The as-
sembly of these oligosaccharide structures takes advantage of
the internalization of lactose by the genetically engineered bac-
teria. After internalization, lactose is used in the cytoplasm as a
platform for the addition of other saccharides by heterologously
expressed glycosyltransferases. Most of the oligosaccharides
produced are secreted into the medium and can be puriﬁed
easily (Bettler et al. 1999; Priem et al. 2002). This approach
of using E. coli as a living factory replaces the time-consuming
and laborious chemical or chemo-enzymatic synthesis and
also allows the large-scale production of oligosaccharides
(Bettler et al. 1999).
The synthesis of oligosaccharides in vivo can be combined
with an approach utilizing the bacterial cell surface as a scaf-
fold for diﬀerent saccharide structures. In Gram-negative
bacteria, the outer membrane is an asymmetric bilayer with
glycerophospholipids in the inner leaﬂet and LPS in the outer
leaﬂet. LPS consists of the lipid A moiety, an inner and an outer
core to which in some organisms a polymeric O-antigen region
is attached (Raetz andWhitﬁeld 2002). The lipid Amoiety com-
prises two glucosamine residues connected through a β1,6
linkage. Acyl chains attached to these glucosamines anchor
the molecule in the outer membrane. Proximal to the lipid A is
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the inner core region. In most Gram-negative bacteria, this
region is composed of two 3-deoxy-D-manno-oct-2-ulosonic
acid (Kdo) and several L-glycero-D-mannoheptose (Hep) resi-
dues which can be substituted by phosphoethanolamine or
hexoses. The distal outer core consists of hexoses and N-acetyl-
hexoses (see Figure 1) (Schnaitman et al. 1991; Parker et al.
1992; Pradel et al. 1992; Schnaitman and Klena 1993; Heinrichs
et al. 1998). To date, ﬁve core types have been found for E. coli
(R1–R4 and K-12), whereas for Salmonella enterica serovar
Typhimurium (S. Typhimurium) only two have been described
(Lüderitz et al. 1982; Heinrichs et al. 1998; Olsthoorn et al.
1998). In S. Typhimurium, the polymeric O-antigen region is
attached to the last glucose residue of the outer core (Hellerqvist
et al. 1969). The outer core structure in E. coli K-12 strains ter-
minates on the heptose residue HepIV to which the O-antigen
region is attached (Holst et al. 1991; Heinrichs et al. 1998).
E. coli K-12 strains used in the laboratory, however, do not
produce the polymeric O16 O-antigen due to an insertion in
wbbL. This gene encodes the rhamnosyltransferase that is in-
volved in the addition of rhamnose to the second position of
the O16 backbone (Liu and Reeves 1994; Stevenson et al.
1994; Yao and Valvano 1994).
Bacterial cell surfaces can be used to display engineered
oligosaccharide structures in their lipopolysaccharide layer
by two diﬀerent pathways. On the one hand, the O-antigen
ligase WaaL dependent transfer of oligo- and polysaccharides
to E. coli or S. Typhimurium lipid A core can be exploited.
The structures transferred include the Haemophilus influenzae
lipooligosaccharide structure, the O-antigens from Shigella
dysenteriae or E. coli O111 as well as the C. jejuni heptasac-
charide normally linked to protein (Spinola et al. 1990; Falt et
al. 1996; Szymanski et al. 1999; Wang et al. 1999; Phillips et
al. 2000; Xu de et al. 2007). This approach requires the assem-
bly of the engineered oligosaccharides on the lipid carrier
undecaprenylpyrophosphate. On the other hand, truncated lip-
id A core structures as acceptors of foreign saccharide
structures can be used. This approach has been employed by
Paton and co-workers for the production of probiotics (Paton
et al. 2001, 2005). The E. coli R1 strain CWG308 with a trun-
cation of the lipid A core at the glucose I residue is used in these
studies to heterologously express glycosyltransferases from C.
jejuni andN. meningitidis. These then modify the truncated lipid
A core to produce a chimeric LOS structure on E. coli. This
system is similar to the “living factory” described above that
employs the glucose moiety of internalized lactose as a plat-
form for the addition of other saccharides.
We extended the approach by Paton and co-workers from E.
coli R1 to E. coli K-12 and S. Typhimurium by constructing
strains that lack the gene encoding the sialic acid aldolase
NanA. This allowed the incorporation of sialic acid into oligo-
saccharides within the cell (Priem et al. 2002). Additionally,
the strains were deleted in glycosyltransferase genes which
led to the truncation of the lipid A core terminating with the
glucose I residue. This was then used to attach the GM3 epi-
tope by the heterologous expression of glycosyltransferases
from N. meningitidis and N. gonorrhoeae.
Results
Truncation of lipid A core in S. Typhimurium and E. coli K-12
and display of the GM3 sugar on the truncated lipid A core
To produce a terminal Glc in E. coliK-12 lipid A core, the genes
encoding the glycosyltranferasesWaaO andWaaBwere deleted.
The resulting strain E. coli K-12 ΔnanAΔwaaOΔwaaB was
termed LPS-1. In S. Typhimurium, the same truncation of the
lipid A core was achieved by deleting the genes encoding the
galactosyltransferases WaaI and WaaB, and the resulting strain
was termed SKI22. Both strains used were also deleted in the
gene encoding the sialic acid aldolase NanA to prevent the
degradation of sialic acid added externally (see below). In or-
der to produce E. coli and S. Typhimurium with a GM3 sugar
epitope on the cell surface, the strains with the truncated lipid
A core, LPS-1 and SKI22, were transformed with a plasmid
encoding the β-1,4-galactosyltransferase LgtE from N. gonor-
rhoeae (pBBRlgtE) and with a plasmid encoding the CMP-
sialic acid synthetase SiaB as well as the sialic acid transferase
Lst from N. meningitidis (pKI3*). The strains containing the
corresponding vectors served as negative control. Strains were
grown in Luria–Bertani (LB) medium supplemented with 2%
sialic acid, and proteinase-K-treated whole cell extracts were
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Fig. 1. Lipopolysaccharide structures in S. Typhimurium (A), E. coli K-12 (B) and the engineered strains for GM3 display (C). Glc, glucose; Gal, galactose; Kdo,
3-deoxy-D-manno-oct-2-ulosonic acid; Hep, L-glycero-D-mannoheptose; GlcNAc, N-acetylglucosamine; NeuNAc, N-acetyl neuraminic acid; P, phosphate; PEtN,
phosphoethanolamine. Adapted from Yethon, Gunn et al. (2000), Yethon, Vinogradov et al. (2000), Frirdich et al. (2003) and Kaniuk et al. (2004).
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prepared. The display of the GM3 structure was judged by silver
staining of a Tris-Tricine polyacrylamide gel electrophoresis
(PAGE). To ﬁrst demonstrate the truncation of the lipid A core,
proteinase-K-treated whole cell extracts of the parental strains
can be seen in lane 1 of Figure 2A for the LPS-1 parent JM107
and in lane 1 of Figure 2B for M525P, the parental strain of
SKI22. These strains show bands of higher apparent molecular
mass than the strains with the truncated core, corresponding to
the full core for JM107 or the full core with additional one or
two O-antigen subunits for M525P. In lane 4 of Figure 2A and
B, the addition of the galactose residue by LgtE was detected
for LPS-1 and SKI22, respectively, by a shift to a higher appar-
ent molecular mass (see Figure 2). The expression of SiaB and
Lst led to the transfer of a sialic acid moiety and a further shift to
a higher apparent molecular mass. This demonstrated that the
GM3 epitope was produced in an E. coli K-12 derivative and
a S. Typhimurium strain and that it was transferred to the trun-
cated lipid A core in both strains. In the strains containing the
plasmids expressing LgtE and Lst/SiaB (lane 5 in Figure 2A
and B), it was observed that the transfer of the sialic acid residue
by Lst was not complete and that some truncated lipid A core
with only galactose added was still present in the preparation.
Live cell microscopy demonstrated surface localization of
GM3 sugar epitope on LPS-1 and SKI22
For immunological studies, it was important that the GM3
sugar epitope was present on the cell surface. As cell surface
localization cannot be judged with whole cell extracts, immu-
noﬂuorescence analysis of live cells was performed. Cells
containing the plasmids encoding the galactosyltransferase
LgtE, the CMP-sialic acid synthetase SiaB and the sialic acid
transferase Lst grown in medium containing sialic acid (see
above) were incubated with a mouse monoclonal anti-GM3
antibody, stained with 4, 6-diamino-2-phenylindole (DAPI)
and an anti-mouse-IgM-Alexa647 conjugate. It is evident
from Figure 3 that the antibody did not bind to cells contain-
ing the truncated core (upper panel) or the truncated core
with the galactose residue attached by LgtE (middle panel).
When the genes encoding Lst and SiaB were expressed, cell
surface staining was visible for E. coli LPS-1 and S. Typhi-
murium SKI22 (lower panel in Figure 3A and B). This
demonstrated that the GM3 sugar epitope was present on
the surface of the bacterial cells, although it was perceivable
again that not all cells carry this epitope.
Matrix-assisted laser desorption/ionization time-of-flight
analysis revealed presence but low abundance of GM3 sugar
epitope on truncated lipid A core
Mass spectrometry was performed for further analysis of the
structures present on the truncated lipid A core of E. coli
LPS-1 and S. Typhimurium SKI22. LOS of the strains display-
ing the GM3 epitope and grown in medium containing sialic
acid were isolated by the method developed by Galanos et al.
(1969). The acyl chains attached at the hydroxyl groups of the
glucosamine residues of the lipid A were cleaved by mild
hydrazine treatment (Haishima et al. 1992). As can be seen
in Figure 4B, the matrix-assisted laser desorption/ionization
time-of-ﬂight (MALDI-TOF) analysis demonstrated that neither
the addition of galactose nor of sialic acid to the lipid A core was
complete in the E. coli LPS-1 strain. In S. Typhimurium SKI22,
the galactose residue was added to nearly all lipid A core mo-
lecules, but sialic acid was not transferred to all galactosylated
lipid A core molecules, similar to the situation in the E. coli
strain (Figure 4D and B). As indicated in Figure 4, the mo-
lecular composition of the truncated lipid A core structure
deducted from the detected mass is a P3–Glc–Hep2–
Kdo2–lipid A structure instead of the reported P4–Glc–Hep3–
Kdo2–lipid A structure (Müller-Loennies et al. 2003). This is
most probably due to the substrate speciﬁcity of the lipid A core
glycosyl- and phosphotransferases andwill be discussed inmore
detail below.
Quantification of display showed higher display levels in E. coli
As means of quantiﬁcation of the display of the GM3 epitope
on the E. coli LPS-1 and the S. Typhimurium SKI22 strains, we
carried out a colorimetric antibody binding assay. For this, live
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Fig. 2. The truncated lipid A core in E. coli LPS-1 (A) and S. Typhimurium
SKI22 (B) can be modiﬁed with a GM3 epitope. Tris-Tricine PAGE of whole
cell extracts from cells which were grown in the presence of external sialic acid
and which expressed the indicated genes from plasmids followed by silver
staining. Whole cell extracts from the parental strains were used as controls.
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Fig. 3. Surface localization of the GM3 epitope on E. coli LPS-1 (A) and S. Typhimurium SKI22 (B). Immunoﬂuorescence analysis of live cells that were grown in
the presence of external sialic acid and which expressed the indicated genes from plasmids. Scale bar 5 µm.
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Fig. 4. MALDI-TOF analysis of puriﬁed, O-deacylated LOS from E. coli LPS-1 and S. Typhimurium SKI22 demonstrates the addition of NeuNAc in the presence
of Lst/SiaB. (A) E. coli LPS-1 expressing the gene encoding for LgtE and containing the vector control for the sialyltransferase. (B) E. coli LPS-1 expressing
the genes encoding for LgtE and Lst/SiaB. (C) S. Typhimurium SKI22 expressing the gene encoding for LgtE and containing the vector control for the
sialyltransferase. (D) S. Typhimurium SKI22 expressing the genes encoding for LgtE and Lst/SiaB.
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cells grown in medium containing sialic acid were incubated
with the anti-GM3 antibody EM5 followed by an incubation
with an anti-mouse-IgM-HRP conjugate. The assay was
developed with the colorimetric substrate 2,2′-azino-bis(3-
ethylbenzthiazoline-6-sulphonic acid) (ABTS) (see Materials
and methods), and the kinetics of the color development were
recorded. This assay demonstrated a 27-fold increase in signal
intensity in the E. coli LPS-1 strain containing LgtE and Lst/
SiaB as compared to the LPS-1 strain harboring the vector con-
trols (Figure 5, left). In S. Typhimurium SKI22, the increase in
signal intensity was 20-fold between SKI22 strain containing
LgtE and Lst/SiaB in comparison to the SKI22 strain with the
vector controls (Figure 5, right). This showed that E. coli
LPS-1 cells bound more anti-GM3 antibody EM5 than the
S. Typhimurium SKI22 cells and thereby indicated higher dis-
play levels of the GM3 sugar epitope on the E. coli strain.
Discussion
The connection between the autoimmune disease GBS and sia-
lylated structures in bacterial LOS is still not clear. The usual
infectious agents associated with subsequent GBS include
Epstein–Barr virus, Mycoplasma pneumoniae, C. jejuni and
cytomegalovirus (Hughes and Cornblath 2005). Of these,
C. jejuni is known to express sialylated LOS that mimics human
gangliosides (Aspinall, Fujimoto et al. 1994; Ang et al. 2004;
Yuki et al. 2004). However, not every structure mimicking gang-
liosides leads to GBS. N. meningitidis and H. influenzae strains
have been demonstrated to produce LOS with a sialyl-LacNAc
structure, which diﬀers from the GM3 epitope only in the
N-acetylgroup present at C2 of the Gal residue (Mandrell et al.
1992; Yamasaki et al. 1993). Nevertheless, none of these strains
has been reported to be a statistically signiﬁcant antecedent in-
fection in GBS patients.
With the aim of providing well-deﬁned model organisms in
order to study the connection between ganglioside mimicry in
the LOS and evocation of an autoimmune disease, we con-
structed E. coli K-12 and S. Typhimurium that display the
GM3 sugar epitope on the cell surface as demonstrated by var-
ious methods. Mass spectrometry analysis of the O-deacylated
isolated LOS proved the addition of galactose and sialic acid re-
sidues to the lipid A core. The molecular mass of the truncated
lipid A core in the E. coli LPS-1 strain (2018 Da) was increased
by 162 and 292 Da, respectively (Figure 5). However, the mo-
lecular mass of 2018 Da for the truncated lipid A core did not ﬁt
with the calculated mass of 2291.95 Da for the chemical com-
position lipid A–Kdo2–Hep3–Hex–P4 of the three main
glycoforms I–II–III present in E. coli K-12 (Müller-Loennies
et al. 2003). The diﬀerence between the calculated and the ob-
served molecular mass could be accounted for by the
disappearance of one heptose residue and one phosphate group.
In E. coli R1, it has been shown that the mutation of waaY
yielded a strain with a core oligosaccharide devoid of phosphate
on the HepII residue. Furthermore, a mutation of waaQ resulted
in the loss of the branched HepIII residue on HepII, and it im-
peded the activity of waaY (Yethon et al. 1998). It is also known
that a mutation of waaG which encodes the glucosyltransferase
acting onHepI not only leads to the truncation of the lipid A core
immediately behind the inner core heptose residues but also to a
lack of phosphate groups on HepII (Yethon, Vinogradov et al.
2000). It is likely that a similar co-dependency between the
monosaccharides present in the lipid A core and the phosphor-
ylation of saccharides exists in E. coli K-12. Most probably, the
deletion ofwaaO andwaaB yields a suboptimal substrate for the
gene product ofwaaQ, thereby inhibiting the addition of the He-
pIII residues. This then ﬁnally results in a lipid A–Kdo2–Hep2–
Hex–P3 structure because the gene product ofwaaY relies on the
presence of the HepIII residue (Yethon et al. 1998). Yethon and
co-workers also demonstrated that the genetic determinants for
modiﬁcations of the lipid A core are conserved between E. coli
and S. Typhimurium (Yethon, Gunn et al. 2000). Therefore, the
structure lipid A–Kdo2–Hep2–Hex2–P3 that we observed for
the galactosylated truncated lipid A core in SKI22 can also be
explained to stem from the same substrate speciﬁcities as in E.
coliK-12. In a S. Typhimurium SKI22 strain containing the vec-
tor controls for LgtE and Lst/SiaB, a product at 2018 Da was
visible, which demonstrates that in S. Typhimurium SKI22
the truncated lipid A core also possesses the structure lipid
A–Kdo2–Hep2–Hex–P3 (data not shown).
While mass spectrometry analysis and lipooligosaccharide
separation by Tris-Tricine polyacrylamide gels demonstrated
the presence of sialic acid on the truncated lipid A core struc-
tures of E. coli LPS-1 and S. Typhimurium SKI22, antibody
binding proved the α-2,3 linkage of the attached sialic acid
residue. A competition assay with puriﬁed sialyllactose, but
not with lactose, demonstrated the accuracy of the antibody
binding (data not shown).
The E. coli and S. Typhimurium strain displaying the
GM3 sugar epitope will be helpful tools when the role of
sialic acid containing LOS structures in the recognition
and the interaction of these structures with the immune sys-
tem is being examined.
Materials and methods
Bacterial strains and growth conditions
A summary of bacterial strains used in this study can be found
in Table I. Bacteria were grown in LB medium (10 g/L Bacto
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Fig. 5. Quantiﬁcation of anti-GM3 binding to whole cells demonstrates higher
display levels in E. coli LPS-1 when compared to S. Typhimurium SKI22. Live
cells expressing the indicated genes from plasmids were incubated with the
anti-GM3 antibody, and the amounts of bound antibody were quantiﬁed by the
colorimetric assay described in the Materials and methods section.
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tryptone, 5 g/L Bacto yeast extracts, 5 g/L NaCl). For sialyla-
tion experiments, LB was supplemented with 2% sialic acid
(Jülich chiral solutions, Jülich, Germany). The pH of the LB
with sialic acid was adjusted to 7.5 by addition of NaOH
and sterilized by ﬁltering. LB agar plates were supplemented
with 1.5% (w/v) agar. Antibiotics were used at the following
ﬁnal concentrations: tetracyclin (tet) 10 µg/mL, ampicillin
(amp) 100 µg/mL, kanamycin 50 µg/mL, chloramphenicol
(cam) 25 µg/mL.
DNA manipulations
N. meningitidis siaB and lst were ampliﬁed from N. meningi-
tidis MC58 (ATCC# BAA 335 D5) genomic DNA, while
H. influenzae lst was ampliﬁed from H. influenzae RM118
genomic DNA (Derek Hood, Oxford). N. gonorrhoeae lgtE
was ampliﬁed from N. gonorrhoeae genomic DNA. Restric-
tion enzymes were purchased from MBI/Fermentas, whereas
ampliﬁcation of DNA was carried out with Pfu DNA poly-
merase isolated in the Institute of Microbiology, ETH
Zurich, by standard protocols. All cloning steps were carried
out in E. coli DH5α, and all constructs were conﬁrmed by
sequencing (Synergene Biotech, Schlieren, Switzerland).
Construction of the E. coli K-12 ΔnanAΔwcaJΔwaaOΔwaaB
strain LPS-1
Inactivation of waaB and waaO was carried out by homolo-
gous recombination using the suicide plasmid pKO3. Primers
(l) and (m) were used for polymerase chain reaction (PCR) am-
pliﬁcation of 0.67 kb of DNA ﬂanking the 5′ end of waaB
from JM107, whereas primers (n) and (o) were used for PCR
ampliﬁcation of 0.69 kb of DNA ﬂanking the 3′ end of waaO.
The 665-bp fragment was digested with BamHI and SalI, while
the 688-bp fragment was digested with BamH1 and SmaI. Both
digested fragments were mixed and cloned into the suicide
plasmid pKO3 digested with SmaI and SalI. The resulting re-
combinant integrative plasmid pKO3-BO was transformed into
TA1ΔnanA cells; positive clones were screened for correct in-
tegration of the plasmid DNA by PCR with primers (l) and (o)
(for the sequence, see Table I). The truncation of wcaJ is de-
scribed elsewhere (Priem et al.).
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Table I. Bacterial strains, plasmids and oligonucleotides used in this study
Bacterial strains
Strain Genotype and phenotype Source or reference
Escherichia coli
DH5α SupE44 ΔlacU169 (Φ80lacZΔM15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 (Hanahan 1983)
JM107 endA1 gyrA96 thi hsdR17 SupE44 relA1λ− Δ(lac-proAB)
[F′ traD36 proAB+ lacIq lacZΔM15]
DSM; (Yanisch-Perron et al. 1985)
TA01 JM 107 ΔnanA (Antoine et al. 2003)
LPS-1 TA01 ΔnanAΔwcaJΔwaaOΔwaa B This study
Salmonella enterica sv. Typhimurium
M525P Wild type (Mastroeni et al. 2000)
SKI2 M525PΔnanA This study
SKI14 M525PΔnanAΔwaaI This study
SKI22 M525PΔnanAΔwaaIΔwaaB This study
Plasmids
Plasmid Genotype Source or reference
pBBR1MCS-3 TetR, bhr ori (Kovach et al. 1995)
pBBRlgtE TetR, bhr ori, N. gonorrhoeae lgtE cloned XbaI/SacI into pBBR1MCS-3 This study
pACT3 CamR, p15A ori (Dykxhoorn et al. 1996)
pKI3* CamR, p15A ori, N. meningitidis lst cloned XbaI/PstI with a C-terminal
FLAG-tag downstream of SiaB from N. meningitidis cloned
SacI/XbaI with a C-terminal c-myc-tag into pACT3
This study
pKD3 bla FRT cat FRT PS1 PS2 oriR6K (Datsenko and Wanner 2000)
pKD4 bla FRT aph FRT PS1 PS2 oriR6K (Datsenko and Wanner 2000)
pKD46 bla PBAD gam bet exo pSC101 oriTS (Datsenko and Wanner 2000)
pCP20 bla cat cI857 λPR flp pSC101 oriTS (Datsenko and Wanner 2000)
Oligonucleotides (5′→3′)
LT2 NanA H1P1 CAGGTATAAAGGTAGGTAGTTAATATATTCATCATCCGTAGAGGTAGGTGTGTAGGCTGGAGCTGCTTC
LT2 NanA H2P2 CACACTGTTGTAGGCCGGGCAAGCGTAGCGCCCCCGGCATTATGCTG CATATGAATATCCTCCTTAGTTCCTATTCC
LT2 I+B H1P1 TATTTCTATCTCAGGAAATGAATCCATTACATCACCTATGGGTTGTGTAGGCTG GAGCTGCTTC
LT2 waaI H2P2 CTATATTTTAAAAATTTTAATAATGCAATATTCTCGAAATTACAAAAGTGA CATATGAATATCCTCCTTAGTTCCTATTCC
LT2 I+B H2P2 GCTATTTAATATCTAAAGTCTTTAGATTAAGGTTTTAACTCTGGGGTATAT CATATGAATATCCTCCTTAGTTCCTATTCC
LT2 waaB H1P1 GTTATAATCTAAAGTCTGTTGAATGACTTCTTCTTCAAAATATTTTCTGCTCATGTGTAGGCTGGAGCTGCTTC
LGTE1 GGATCCAGGAGTAAATAATGCAAAACCACGTTATCAGCTTGGC
LGTE2 GAGCTCTTTTAATCCCCTATATTTTACAC
Lst Fw/XbaI new AGTCTAGAAATTTGTCGGAATGGAGTTTTAG
Lst Rev/PstI FLAG new AACCTGCAGTCACTTGTCGTCGTCGTCCTTGTAGTCATTTTTATCGTCAAATGTCAAAATC
SiaB Fw/SacI AGAGCTCCTGCTCAAAAACGTTTTATCGATTTG
SiaB Rev/XbaI
c-myc new
AATCTAGATCACAGATCCTCTTCTGAGATGAGTTTTTGTTCGCTTTCCTTGTGATTAAGAATGTTTTC
l CCCGGGTCGTGATAAAGGGCGTCTTC
m TTAGGATCCACCTTCCAGCCATCCCTTAT
n GGATCCAAAGCACTCGCGGCCGCAAAGCTTGCAGAGCAAAACC
o GTCGACCATCTTTCCAGGGGGAATTT
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Construction of the M525PΔnanAΔwaaIΔwaaB strain SKI22
For the step-by-step deletion of the nanA,waaI andwaaB genes,
the method introduced by Datsenko and Wanner was used
(Datsenko and Wanner 2000). Primers and plasmids employed
in this approach are listed in Table I. First, the gene encoding
the sialic acid aldolase NanA was deleted. DNA sequences
from template plasmid pKD4 which carries a kanamycin
resistance cassette ﬂanked by FLP recognition target (FRT)
sites were ampliﬁed using primers LT2 NanA H1P1 and
LT2 NanA H2P2. The PCR product obtained was electropo-
rated into strain M525P carrying the λ red recombinase
encoding plasmid pKD46. Transformants in which the nanA
gene had been exchanged with the kanamycin resistance cas-
sette were selected on LB plates containing 50 µg/mL ﬁnal
concentration kanamycin. Integration of the antibiotic cassette
into the correct genomic region was veriﬁed by PCR. Loss of
the antibiotic cassette from the chromosome was achieved by
using pCP20 which encodes the FLP recombinase and recog-
nizes the FRT sites. The resulting ΔnanA strain was termed
SKI2 after veriﬁcation of the genomic deletion of nanA by
PCR. In SKI2, the waaI gene was deleted using the same
approach and primers LT2 I+B H1P1 and LT2 waaI H2P2.
The resulting ΔnanAΔwaaI strain was termed SKI14 after
veriﬁcation of the genomic deletion of waaI by PCR. In
SKI14, the waaB gene was deleted using the same approach
again and primers LT2 waaB H1P1and LT2 I+B H2P2. The
resulting ΔnanAΔwaaIΔwaaB strain was termed SKI22 after
veriﬁcation of the genomic deletion of waaB by PCR.
Analysis of lipid A core
Detection of lipid A core and its alteration was performed by
silver staining. To achieve this, proteinase-K-treated whole cell
extracts were prepared as follows: The equivalent of 1 OD600
of induced overnight LPS-1 or SKI22 cells harboring pBBRlgtE
and pKI3* (or the corresponding vector controls) or the parental
strains JM107 or M525P were resuspended in 500 µL 0.065 M
Tris-HCl pH 6.8, 2% sodium dodecyl sulfate (w/v), 5% β-
mercaptoethanol (v/v), 10% glycerin (v/v) and 0.05% bromo-
phenol blue (w/v) and lysed for 5 min at 95°C. Proteins were
digested by the addition of proteinase K (Roche, ﬁnal concen-
tration 0.4 mg/mL) for 1 h at 60°C. Equal volumes of each
sample were then separated on a 17% Tris-Tricine-PAGE and
stained with silver as described (Tsai and Frasch 1982).
Live cell microscopy
For live cell microscopy, the equivalent of 0.2 OD600 of in-
duced overnight LPS-1 or SKI22 cells harboring pBBRlgtE
and pKI3* (or the corresponding vector controls) were pelleted
by centrifugation (8 min, 4°C, 8000 × g) and washed once with
1 mL phosphate-buﬀered saline (PBS). The samples were then
treated with 5% bovine serum albumin (BSA) in PBS on a ro-
tary wheel for 30 min at 4°C. Incubation with the primary
GM3 recognizing antibody EM5 (Hugh Willison, Glasgow)
in PBS/5% BSA followed for 45 min at 4°C on a rotary wheel.
Unbound antibody was washed away in two washing steps us-
ing 1 mL PBS. Cells were then stained with DAPI (10 μg/mL
ﬁnal concentration), and bound antibody was visualized with a
goat-anti-mouse-IgM-AlexaFluor647 conjugate (Invitrogen) in
a 45-min incubation step on ice in the dark. Unbound DAPI and
secondary antibody were removed by washing the cells three
times with PBS. Finally, cells were resuspended in 60 μL
PBS for analysis under the microscope (Zeiss Axioplan 2), em-
bedded in low melting agarose. Data acquisition and analysis
for microscopy was carried out with Zeiss Axiovision 4.7,
while images were combined using Adobe Photoshop CS3.
Colorimetric antibody binding quantification to whole cells
The procedure used for quantiﬁcation of anti-GM3 antibody
EM5 binding to whole cells was the same as for live cell micros-
copy up to the incubation step with the secondary antibody. As
secondary antibody, a goat-anti-mouse-IgM-horse radish pero-
xidase conjugate (Santa Cruz) was used in PBS/5% BSA in an
incubation step of 45 min at 4°C on a rotary wheel. Unbound
horse radish peroxidase conjugate was washed away in two
washing steps; cells were resuspended in 500 μL 70 mM phos-
phocitrate buﬀer pH 4.2 and distributed in triplicates in a 96-
well plate. A ﬁrst measurement for OD600 was carried out before
adding the substrate ABTS (ﬁnal concentration 1 mM in 70 mM
phosphocitrate buﬀer pH 4.2 with addition of 0.03% H2O2) to
the wells and recording the color development at 405 nm for 5
min in a SpectraMaxPlus (Molecular Devices). For analysis,
vmax was normalized to OD600.
Isolation of lipooligosaccharides
LOS of overnight induced LPS-1 or SKI22 cells harboring
pBBRlgtE and pKI3* (or the corresponding vector controls)
was extracted using the phenol–chloroform–light petroleum
method (Galanos et al. 1969). In brief, cells equivalent to ap-
proximately 4000 OD600 were harvested and washed with 1×
PBS. The bacteria were then resuspended in phenol:chloro-
form:light petroleum (1:2.5:4) at a ﬁnal concentration of 2 g
per 50 mL and disrupted in a potter homogenizer. Samples
were spun for 10 min at 4°C at 3800 × g, and the supernatant
was incubated at 55°C in a water bath until complete evapora-
tion of the chloroform-ether phase had taken place. LPS was
precipitated by the addition of 1 volume of deionized H2O
and pelleted for 10 min at 4°C at 3800 × g. At this stage, three
separate layers were visible in the suspension, H2O in the up-
per phase, LOS in the middle phase and phenol in the lower
phase. The phenol phase was removed with a Pasteur pipette,
and a second precipitation of LOS from the phenol phase was
performed by the addition of 1 volume of deionized H2O, and
the centrifugation step was repeated. Both LOS phases were
combined and spun at 4°C for 15 min at 11,000 × g. Residual
phenol was removed with a Pasteur pipette, and the centrifuga-
tion step was repeated. The pellet containing the LOS was
washed with 20 mL methanol, spun for 20 min at 17,500 × g,
and the supernatant was discarded. Residual methanol was re-
moved by heating the sample in a water bath to 55°C. The
LOS pellet was resuspended in 10 mL of 0.1 mM MgCl2 and
centrifuged at 15°C, 100,000 × g for 16 h. The ﬁnal pellet was
resuspended in 2 mL of ddH2O and dried down in a vacuum.
O-deacylation of isolated lipooligosaccharides
O-deacylation of LPS was performed by mild hydrazine treat-
ment (Haishima et al. 1992). LPS was dissolved in hydrazine
hydrate to a ﬁnal concentration of 20 mg/mL and incubated for
2 h at 37°C with constant shaking. To precipitate LPS after the
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cleavage of theO-linked acyl chains, 15 volumes of ice-cold ac-
etone were added. The sample was spun for 15 min at room
temperature at 16,000 × g, and the pellet containing the
O-deacylated LPS was washed with acetone and subjected
to another centrifugation step for 15 min at room temperature
at 10,000 × g. The supernatant was removed and the pellet
air dried.
Mass spectrometry analysis
For MALDI-mass spectrometry proﬁling, samples dissolved
in water at a ﬁnal concentration of 5–10 mg/mL were mixed
1:1 with the 6-aza-2-thio-thymine (ATT) matrix (20 mg/mL
in 70% MeOH with 10 mM ammonium citrate). Data acquisi-
tion was performed on 4800 Peoteomic Analyzer, (Applied
Biosystem, Framingham, MA) using linear negative ion
mode, with a total of 20 sub-spectra of 125 laser shots and each
with laser energy set at 7000.
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